Diabetes and cardiovascular disease: The role of glycemic control

Current Diabetes Reports

Volumn 9, Issue 1, 2009, Pages 65-72

  Cheng, Alice Y Y ^b   Leiter, Lawrence A ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; METFORMIN; PERINDOPRIL; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG SAFETY; EARLY INTERVENTION; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS;

EID: 59749088634     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0012-y     Document Type: Review

References (19)

1. Deedwania P, Kosibrorod M, Barrett E, et al.: Hyperglycemia and acute coronary syndrome: A scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008, 117:1610-1619.
2. Capes SE, Hung D, Malmberg K, Gerstein HC: Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic review. Lancet 2000, 355:773-778.
3. Gerstein HC: Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. Evid Based Cardiovasc Med 1997, 1:87-88.
4. Punthakee Z, Werstuck GH, Gerstein HC: Diabetes and cardiovascular disease: Explaining the relationship. Rev Cardiovasc Med 2007, 8:145-153.
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
6. Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. N Engl J Med 2005, 353:2643-2653.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837-853.
8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352: 854-865.
9. Action to control cardiovascular risk in diabetes (ACCORD) trial: Design and methods. The ACCORD Study Group [no authors listed]. Am J Cardiol 2007, 99(Suppl):21i-33i.
10. Effects of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group [no authors listed]. N Engl J Med 2008, 358:2545-2559.
11. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group [no authors listed]. N Engl J Med 2008, 358:2560-2572.
12. Patel A, MacMahon S, Calmers J, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. ADVANCE Collaborative Group. Lancet 2007, 370:829-840.
13. Chalmers J: ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) Trial Results. Presented at the 44th European Association for the Study of Diabetes Annual Meeting. Rome, Italy; September 7-11, 2008.
14. Duckworth WC, Moritz TE: Glycemic Control and Cardiovascular Outcomes - the VA Diabetes Trial (Symposium). Presented at the 68th Scientific Sessions of the American Diabetes Association. San Francisco, CA; June 6-10, 2008.
15. Abraria C, Duckworth WC, Del Prato S: VA Diabetes Trial Results. Presented at the 44th European Association for the Study of Diabetes Annual Meeting. Rome, Italy; September 7-11, 2008.
16. Holman RR, Sanjoy KP, Bethel A, et al.: 10-Year follow-up of intensive glycemic control in type 2 diabetes. N Engl J Med 2008, 359: 1577-1589. Available at http://content.nejm.org/cgi/content/abstract/359/15/1577. Accessed October 16, 2008.
17. Dluhy RG, McMahon GT: Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008, 358:2630-2633.
18. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
19. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.